Dataset from A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin ≥1500 mg in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin,
in addition to metformin, results in better glycemic control, as measured by HbA1c, over a
treatment period of 52 weeks, compared to the addition of glimepiride to metformin in
subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on Metformin
Alone. We will compare the change from baseline in HbA1c achieved with saxagliptin, in
co-administration with dapagliflozin, added to current background therapy with metformin
compared to glimepiride added to current background therapy with metformin ≥1500 mg at Week
52.